Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Leases (2019 - 2026)

Insight Molecular Diagnostics' Leases history spans 7 years, with the latest figure at $1.1 million for Q4 2025.

  • On a quarterly basis, Leases fell 33.77% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 33.77% decrease, with the full-year FY2025 number at $1.1 million, down 33.77% from a year prior.
  • Leases hit $1.1 million in Q4 2025 for Insight Molecular Diagnostics, down from $2.3 million in the prior quarter.
  • Over the last five years, Leases for IMDX hit a ceiling of $4.0 million in Q2 2023 and a floor of $537000.0 in Q2 2021.
  • Historically, Leases has averaged $2.5 million across 5 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Leases: plummeted 84.19% in 2021 and later surged 551.58% in 2022.
  • Tracing IMDX's Leases over 5 years: stood at $3.5 million in 2021, then crashed by 37.73% to $2.2 million in 2022, then dropped by 24.87% to $1.6 million in 2023, then rose by 2.2% to $1.7 million in 2024, then tumbled by 33.77% to $1.1 million in 2025.
  • Business Quant data shows Leases for IMDX at $1.1 million in Q4 2025, $2.3 million in Q3 2025, and $2.5 million in Q2 2025.